Skip to main content
. 2019 Apr 26;11(5):945. doi: 10.3390/nu11050945

Table 3.

A brief summary of the selected articles using omega-3 PUFAs as treatment for depression.

Authors Clinical or Experimental Condition Species Treatment Scheme Major Outcome
Chhetry et al, 2016 [143] MDD Human 4 g 1 FO (1.6 g EPA + 0.8 g DHA) Improved MDD-related white matter deficiency
Smith et al., 2017 [129] MDD Human 260 mg or 520 mg DHA 54% of patients showed a reduction of depression severity ≥ 50%
Wu et al., 2018 [144] Chemotherapy-induced depression Rat 1.5 g/kg omega-3 PUFAs (34% EPA + 24% DHA) PUFAs inhibited depressive-like behaviors (p < 0.001)
Dang et al., 2018 [133] LPS-induced depression Rat 1.5 g/kg omega-3 PUFAs (34% EPA + 24% DHA) Omega-3 PUFAs decreased depressive behavior (p < 0.001)
Nishinaka et al., 2014 [137] Behavioral despair paradigm Mice GW9508 (1.0, 10 or 25 µg/mouse) i.c.v FFA1 activation decreased immobility in a tail suspension test (p < 0.05)
Deyama et al., 2017 [140] LPS-induced depression Mice RvD1 (10 ng i.c.v.) or RvD2 (10 ng i.c.v.) Both treatments inhibited depressive-like behaviors (p < 0.005)
Deyama et al., 2018 [141] LPS-induced depression Mice RvE3 (10 and 100 ng i.c.v.) Inhibition of depressive behavior (p < 0.005)
Ishikawa et al., 2017 [142] Chronic unpredictable stress-related depression Mice RvD1 (10 ng i.c.v.) or RvD2 (10 ng i.c.v.) Both treatments inhibited depressive behavior for 24 h (p < 0.05)

1 FO: Fish oil.